2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
531 Views
Pharmaron Beijing: Trading Debut, Valuation Scenario Analysis
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
415 Views
Hong Kong Buyback Weekly: Yichang HEC, Viva Biotech, China Literature Led the Buybacks
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Yichang Hec Changjiang Pharmaceutical Co., Ltd. (1558...
277 Views
Pharmaron Beijing IPO: H-Share Valuation Enticing
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
586 Views
Pharmaron Beijing IPO: Solid 9M19, but Is It Good Enough?
Pharmaron Beijing Co., Ltd. (A) (300759 CH) is a global contract research organisation (CRO) and is one of the top three drug discovery service...
407 Views